10th International Congress on Genitourinary Malignancies

The 10th International Congress on Genitourinary Malignancies will provide a comprehensive review of current therapeutic strategies for the treatment of all stages of kidney, bladder, and prostate cancers, including clinical and molecular disease characterization, prevention, prognostication, multimodality management of disease, and new therapeutic agents. Interactive panel discussions and case-based vignettes will provide practical clinical context for the interpretation of the presented trial data. Faculty recommendations and an interactive tumor board discussion will aid in transitioning treatment standards to individualized care in the practice setting. Participants will be able to apply the latest advances in the treatment of genitourinary malignancies to their daily practice and discuss future directions in research and clinical trials.

At the conclusion of this congress, you should be able to:

Differentiate patient prognostic groups based on pretreatment risk features in renal cell carcinoma
Incorporate current standards into the surgical and clinical management of patients with localized renal cell carcinoma
Select appropriate targeted therapies for the treatment of advanced renal cell carcinoma based on patient characteristics and prior therapy
Evaluate the efficacy and safety of different sequential and combination therapy options for advanced renal cell carcinoma
Discuss emerging therapies and therapeutic strategies in the refractory/resistant setting for renal cell carcinoma
Monitor and provide supportive therapy for treatment-related toxicities in patients with advanced renal cell carcinoma
Incorporate current evidence-supported treatment, including surgical and systemic therapy options, into the management of all stages of bladder cancer
Identify genetic markers associated with prognosis in prostate cancer
Appraise the risk-benefit profile of chemoprevention strategies for individual patients with prostate cancer
Integrate updated concepts for multimodality treatment, including surgery, radiation therapy, and hormonal therapy, into the management of patients with localized and high-risk prostate cancer
Apply appropriate chemotherapy to the management of castrate-resistant prostate cancer
Evaluate the role of novel immunotherapies and targeted agents in the treatment of castrate-resistant prostate cancer
Assess the genesis of therapy resistance in prostate cancer and renal cell carcinoma
Assess the role of bone-targeted therapies in the management of patients with advanced prostate cancer
This educational program is directed toward medical, surgical, and radiation oncologists and urologists interested in the treatment of patients with genitourinary malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists,